Prenetics Global Limited announced a Board-authorized $40 million share repurchase program over 12 months, backed by $164 million in total adjusted liquidity and zero debt as of March 1, 2026. Executives invested $2.75 million personally, with IM8 targeting $180M-$200M revenue in 2026 and adjusted EBITDA profitability by Q4 2027.
Key takeaways
Board authorized $40M share repurchase program for Class A Ordinary Shares over 12 months
Management and Board committed up to $42.75M total including $2.75M executive personal purchases
Total adjusted liquidity $164M as of March 1, 2026 with zero debt
IM8 targeting $180M-$200M revenue in 2026
Adjusted EBITDA profitability targeted by Q4 2027
Recent divestitures: ACT Genomics (~$46M gross cash), Europa Distribution (up to $13M stock), Insighta 35% stake ($70M cash)